Compositions comprising TL1A-Ig fusion protein for the regulation of T regulatory cells, and methods for their use
US9603925B2 · kind B2 · utility
6Cited by
58References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2014 |
| Grant date | Mar 28, 2017 |
| Priority date | — |
| Expiry date | May 13, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.